Outlook Therapeutics’ (OTLK) “Neutral” Rating Reiterated at Chardan Capital

Outlook Therapeutics (NASDAQ:OTLK)‘s stock had its “neutral” rating reissued by investment analysts at Chardan Capital in a research note issued to investors on Monday, Marketbeat Ratings reports.

Several other equities research analysts have also weighed in on OTLK. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Outlook Therapeutics in a research report on Friday, November 29th. BTIG Research cut their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, November 29th. Finally, Ascendiant Capital Markets lowered their target price on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Outlook Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $42.34.

Outlook Therapeutics Price Performance

NASDAQ:OTLK opened at $1.80 on Monday. The firm has a market capitalization of $42.59 million, a PE ratio of -0.17 and a beta of 0.46. The business’s fifty day moving average price is $5.14 and its 200 day moving average price is $6.62. Outlook Therapeutics has a 12 month low of $0.87 and a 12 month high of $12.85.

Insider Transactions at Outlook Therapeutics

In other Outlook Therapeutics news, CFO Lawrence A. Kenyon purchased 5,000 shares of Outlook Therapeutics stock in a transaction dated Thursday, September 26th. The stock was acquired at an average cost of $5.69 per share, with a total value of $28,450.00. Following the acquisition, the chief financial officer now directly owns 5,946 shares of the company’s stock, valued at $33,832.74. This represents a 528.54 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.40% of the company’s stock.

Institutional Trading of Outlook Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Christensen King & Associates Investment Services Inc. purchased a new stake in Outlook Therapeutics during the third quarter worth $55,000. AQR Capital Management LLC acquired a new position in Outlook Therapeutics during the second quarter worth about $75,000. Barclays PLC grew its position in shares of Outlook Therapeutics by 677.4% in the third quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after purchasing an additional 18,249 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Outlook Therapeutics during the 3rd quarter worth approximately $199,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Outlook Therapeutics during the 2nd quarter worth approximately $232,000. Institutional investors and hedge funds own 11.20% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.